Home The Word Brain My Amedeo FAQ Privacy About   


Amedeo C49

English + 你好 (nǐ hǎo) = limitless possibilities.
Start learning Mandarin Chinese today—for free, forever.

Amedeo C49 is completely free, for life. Next week: +49.


  Bladder Cancer

  Free Subscription


22.09.2025

2 Am J Transl Res
1 Arch Ital Urol Androl
1 BJUI Compass
2 Cancer Med
1 Cancer Rep (Hoboken)
2 Cancers (Basel)
1 Chembiochem
1 Chin Med J (Engl)
1 Clin Cancer Res
3 Clin Genitourin Cancer
2 Cureus
1 Curr Opin Urol
2 Front Immunol
1 Histol Histopathol
1 Int Braz J Urol
1 Int Immunopharmacol
1 Int J Biol Sci
1 Int J Med Sci
1 Int J Mol Sci
2 Int J Surg
1 J Immunother Cancer
1 J Manag Care Spec Pharm
1 J Pathol
1 J Racial Ethn Health Disparities
1 J Robot Surg
1 JCO Precis Oncol
2 Medicine (Baltimore)
1 Nat Med
1 Oncogene
1 Pathol Res Pract
1 Radiol Oncol
1 Transl Androl Urol
2 Transl Oncol
1 World J Urol


   Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Am J Transl Res

  1. GOTO T, Akai T, Teramoto Y, Miyamoto H, et al
    Latrophilin-1 and latrophilin-2 as androgen receptor-responsive G protein-coupled receptors promote bladder cancer progression.
    Am J Transl Res. 2025;17:6403-6413.
    PubMed         Abstract available

  2. SHAO Y, Guan Y, Zhao J, Abudurexiti M, et al
    Alternating intravesical instillation of Bacillus Calmette-Guerin and Pseudomonas aeruginosa effectively prevents postoperative recurrence in high-risk non-muscle-invasive bladder cancer.
    Am J Transl Res. 2025;17:6619-6629.
    PubMed         Abstract available


    Arch Ital Urol Androl

  3. LOPES M, Pereira J, Temido MJ, Gama J, et al
    Prognostic value of combined tumor regression grade and TNM stage in muscle-invasive bladder cancer treated with neoadjuvant chemotherapy and radical cystectomy.
    Arch Ital Urol Androl. 2025 Sep 17:14264. doi: 10.4081/aiua.2025.14264.
    PubMed         Abstract available


    BJUI Compass

  4. HIONG A, Lynam J, Weickhardt A, Wong S, et al
    Perioperative chemotherapy use and related outcomes in muscle-invasive bladder cancer in Australia.
    BJUI Compass. 2025;6:e70083.
    PubMed         Abstract available


    Cancer Med

  5. ISHII N, Sekine Y, Shinohara M, Kawashima Y, et al
    Effects of Avelumab Maintenance on Advanced Urothelial Carcinoma: A Real-World Multicenter Study.
    Cancer Med. 2025;14:e71241.
    PubMed         Abstract available

  6. HUANG X, Wang X, He Z, Huang Y, et al
    Mechanisms, Clinical Trials, and New Treatments for BCG-Unresponsive in Nonmuscle Invasive Bladder Cancer.
    Cancer Med. 2025;14:e71243.
    PubMed         Abstract available


    Cancer Rep (Hoboken)

  7. URUSHIBARA M, Kato D, Okumura T, Kojima A, et al
    Long-Term Survival Obtained by Repeated Cytoreductive Surgery and S-1 Plus Cisplatin Chemotherapy at Each Instance of Disease Progression in a Patient With Metastatic Urachal Carcinoma: A Case Report.
    Cancer Rep (Hoboken). 2025;8:e70317.
    PubMed         Abstract available


    Cancers (Basel)

  8. DEVAR J, Elebo N, Makan A, Pincus A, et al
    Distinct Metabolomic and Lipoprotein Signatures in Gall Bladder Cancer Patients of Black African Ancestry.
    Cancers (Basel). 2025;17:2925.
    PubMed         Abstract available

  9. SETTI BOUBAKER N, Gurtner A, Boussetta S, Manni I, et al
    Dysregulated MicroRNAs in Urinary Non-Muscle-Invasive Bladder Cancer: From Molecular Characterization to Clinical Applicability.
    Cancers (Basel). 2025;17:2768.
    PubMed         Abstract available


    Chembiochem

  10. GRIMMEISEN M, Wang X, Weldle M, Sartory K, et al
    Synthesis and Evaluation of Trehalose-Based Mertansine Warheads for Bacillus Calmette-Guerin Delivery of Anticancer Agents.
    Chembiochem. 2025;26:e202500390.
    PubMed         Abstract available


    Chin Med J (Engl)

  11. WANG J, Yang J, Yao K, Tan J, et al
    m6A-modified circCD2AP suppressed ferroptosis in bladder cancer by upregulating FOXC1 to promote PARK7 transcriptional activity.
    Chin Med J (Engl). 2025 Sep 16. doi: 10.1097/CM9.0000000000003744.
    PubMed         Abstract available


    Clin Cancer Res

  12. STOCKEM CF, Gil-Jimenez A, Ali H, van Dorp J, et al
    Biomarker Analysis and Treatment Dynamics Following Preoperative Ipilimumab plus Nivolumab in Locally Advanced Urothelial Cancer from the Phase IB NABUCCO Study.
    Clin Cancer Res. 2025;31:3897-3906.
    PubMed         Abstract available


    Clin Genitourin Cancer

  13. HAN T, Cui H, Du G, Guan Y, et al
    Expression and Prognostic Significance of Different Antibody-Drug Conjugate Target Proteins in Urachal Carcinoma.
    Clin Genitourin Cancer. 2025;23:102403.
    PubMed         Abstract available

  14. HAN W, Yu X, Chen S, Ou Z, et al
    Clinical Characteristics and Surgical Outcomes of Bladder Paraganglioma: A 20-Year Nationwide Center Experience.
    Clin Genitourin Cancer. 2025;23:102397.
    PubMed         Abstract available

  15. SLUSARCZYK A, Scilipoti P, Contieri R, Longoni M, et al
    Comparative Assessment of Chemotherapy Followed by Consolidative Radical Cystectomy Versus Chemoradiation for Clinically Node-Positive Urothelial Carcinoma of the Bladder.
    Clin Genitourin Cancer. 2025;23:102399.
    PubMed         Abstract available


    Cureus

  16. IBRAHEEM N, Abosheisha M, Alemam A, Abbas M, et al
    Integrated Magnetic Resonance Imaging in Muscle-Invasive Bladder Cancer: A Comprehensive Review.
    Cureus. 2025;17:e90077.
    PubMed         Abstract available

  17. SHEBANI MAA, Ikdees AA, Alazeebi SY, Nagib E, et al
    A Multifactorial Case of Retroperitoneal Fibrosis in a Post-radiation Bladder Cancer Patient: Diagnostic and Therapeutic Challenges.
    Cureus. 2025;17:e89976.
    PubMed         Abstract available


    Curr Opin Urol

  18. OUALLA K, Alem M, Teoh J
    Systemic immunotherapy for BCG unresponsive nonmuscle-invasive bladder cancer.
    Curr Opin Urol. 2025 Sep 15. doi: 10.1097/MOU.0000000000001334.
    PubMed         Abstract available


    Front Immunol

  19. LANG Y, Li P, He R, Zhu B, et al
    Dynamic changes of urinary microbiota in patients with bladder cancer after surgery and its clinical significance.
    Front Immunol. 2025;16:1638628.
    PubMed         Abstract available

  20. CAO J, Zheng W
    Angiogenesis-related gene NID2 profiling and immune infiltration in bladder cancer: prognostic implications and immunotherapy response.
    Front Immunol. 2025;16:1615173.
    PubMed         Abstract available


    Histol Histopathol

  21. OHMOTO A, Kitahama K, Shigematsu Y, Hayashi N, et al
    Genomic features of bladder neuroendocrine carcinoma with composite histology.
    Histol Histopathol. 2025;40:1547-1554.
    PubMed         Abstract available


    Int Braz J Urol

  22. SIMOES GCS, Calderon J, Claros OR, Alfer W, et al
    Robotic Partial Cystectomy for Urachal Adenocarcinoma: Surgical Technique with Cys-toscopic Correlation.
    Int Braz J Urol. 2026;52:e20250446.
    PubMed         Abstract available


    Int Immunopharmacol

  23. MA B, Ma C, Long X, Jiang L, et al
    Stromal reprogramming in urachal cancer: Fibroblast activation protein and collagen remodeling drive immune-suppressive niches and immunotherapy resistance.
    Int Immunopharmacol. 2025;163:115204.
    PubMed         Abstract available


    Int J Biol Sci

  24. HAN Y, Li C, Wu G
    Comment on "IGF2BP3 promotes the proliferation and cisplatin resistance of bladder cancer by enhancing the mRNA stability of CDK6 in an m(6)A dependent manner".
    Int J Biol Sci. 2025;21:5284-5286.
    PubMed        


    Int J Med Sci

  25. CHEN H, Ma L, Ji Z, Dong J, et al
    FAM174B remodels the tumor microenvironment, inhibits the infiltration of macrophage, predicts the molecular subtype and therapeutic response of bladder cancer.
    Int J Med Sci. 2025;22:3737-3748.
    PubMed         Abstract available


    Int J Mol Sci

  26. DAVIDSSON S, Jerlstrom T, Carlsson J
    Optimizing Tissue Sampling Timing for Accurate Gene Expression Analysis.
    Int J Mol Sci. 2025;26:8581.
    PubMed         Abstract available


    Int J Surg

  27. LIU L, Li JP, Gao LX, An L, et al
    Risk factors for acute kidney injury following radical cystectomy: a systematic review and meta-analysis.
    Int J Surg. 2025;111:6330-6342.
    PubMed         Abstract available

  28. LIU L, He LY, Zhang PY, Xiao Y, et al
    Neuroendocrine carcinoma of the bladder: do they have a worse prognosis? A large retrospective cohort study by propensity score matching analysis.
    Int J Surg. 2025;111:6435-6440.
    PubMed         Abstract available


    J Immunother Cancer

  29. HABAZ IA, Ou X, Wang NI, Schincaglia A, et al
    MAIT cells promote cancer progression and regulatory T cell accumulation in bladder tumor microenvironment.
    J Immunother Cancer. 2025;13:e012496.
    PubMed         Abstract available


    J Manag Care Spec Pharm

  30. SQUIRES P, Cook EE, Song Y, Wang CY, et al
    Real-world economic burden of disease recurrence in patients with muscle-invasive bladder cancer: A population-level claims-based analysis.
    J Manag Care Spec Pharm. 2025 Sep 17:1-11. doi: 10.18553/jmcp.2025.25106.
    PubMed         Abstract available


    J Pathol

  31. YANG T, Sun X, Chen J, Li J, et al
    MS4A4A-positive tumor-associated macrophages associate with poor prognosis and T-cell exhaustion in patients with urothelial carcinoma of the bladder.
    J Pathol. 2025;267:225-239.
    PubMed         Abstract available


    J Racial Ethn Health Disparities

  32. DE ANGELIS M, Jannello LMI, Siech C, Di Bello F, et al
    Race/Ethnicity Affects Access and Survival Differences After Neoadjuvant or Adjuvant Chemotherapy at Radical Cystectomy in Urothelial Carcinoma Patients.
    J Racial Ethn Health Disparities. 2025;12:3284-3293.
    PubMed         Abstract available


    J Robot Surg

  33. PARK IW, Noh TI, Kang SH, Oh JJ, et al
    Demonstrating the non-inferiority of robotic radical cystectomy for cT3-cT4 urothelial carcinoma in the era of neoadjuvant chemotherapy: a propensity score-matched analysis.
    J Robot Surg. 2025;19:596.
    PubMed         Abstract available


    JCO Precis Oncol

  34. GUPTA S, Lee JK, Mitchell J, Huang RSP, et al
    Fibroblast Growth Factor Receptor 3 Alteration Status and Outcomes on Immune Checkpoint Inhibitors in Patients With Metastatic Urothelial Carcinoma.
    JCO Precis Oncol. 2025;9:e2500257.
    PubMed         Abstract available


    Medicine (Baltimore)

  35. LIU Z, Tu J, Long J, Guo L, et al
    Causal relationships between immune cells and common urinary system tumors: A bidirectional analysis of Mendelian randomization.
    Medicine (Baltimore). 2025;104:e44297.
    PubMed         Abstract available

  36. LIU Y, Li J, Liang G, Fang F, et al
    The mediating effect of dyadic coping between illness perception and fear of disease progression in bladder cancer patients: A cross-sectional survey.
    Medicine (Baltimore). 2025;104:e44520.
    PubMed         Abstract available


    Nat Med

  37. GALSKY MD, Bajorin DF, Tomita Y, Ye D, et al
    Adjuvant nivolumab in muscle-invasive urothelial carcinoma: exploratory biomarker analysis of the randomized phase 3 CheckMate 274 trial.
    Nat Med. 2025;31:3062-3073.
    PubMed         Abstract available


    Oncogene

  38. XIE J, Zhang H, Wang K, Ni J, et al
    Correction: M6A-mediated-upregulation of lncRNA BLACAT3 promotes bladder cancer angiogenesis and hematogenous metastasis through YBX3 nuclear shuttling and enhancing NCF2 transcription.
    Oncogene. 2025 Sep 17. doi: 10.1038/s41388-025-03575.
    PubMed        


    Pathol Res Pract

  39. KHANI F, Beg S, Park K, Kawaguchi K, et al
    SPINK1 immunohistochemistry: An ancillary tool to diagnose urothelial carcinoma in situ and urothelial dysplasia.
    Pathol Res Pract. 2025;273:156148.
    PubMed         Abstract available


    Radiol Oncol

  40. MARKOVIC G, Resnik N, Janev A, Zupancic D, et al
    The role of focal adhesion kinase in bladder cancer: translation from in vitro to ex vivo human urothelial carcinomas.
    Radiol Oncol. 2025;59:349-367.
    PubMed         Abstract available


    Transl Androl Urol

  41. HASHIMOTO M, Fukiage K, Taniguchi K, Minami T, et al
    Upper urinary tract urothelial carcinoma patients show better overall response rate than bladder cancer patients during enfortumab vedotin treatment following pembrolizumab.
    Transl Androl Urol. 2025;14:2279-2288.
    PubMed         Abstract available


    Transl Oncol

  42. TIAN S, Wang C, Zhao X, Xuan Y, et al
    A CEBPB/TYMP/GDF15 signaling axis mediates tumor growth and cisplatin resistance in bladder cancer.
    Transl Oncol. 2025;61:102537.
    PubMed         Abstract available

  43. LAI Y, Peng Z, He Z, Lu Z, et al
    Dioscin initiates dual roles in bladder cancer progression via miR-195-5p/FASN/SLC3A2 axis-mediated cell death mechanisms.
    Transl Oncol. 2025;61:102534.
    PubMed         Abstract available


    World J Urol

  44. WILLIAMS C, Talwar R, Ramchandani P, Smith AL, et al
    Characterizing pelvic organ descent in women after radical cystectomy: an exploratory analysis.
    World J Urol. 2025;43:559.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Bladder Cancer is free of charge.